FDA Issues Clinical Development Guidance for Gastroparesis Drugs

Drug Industry Daily
A A
The FDA names five acceptable endpoints for trials of gastroparesis treatments in a draft guidance released last week.

To View This Article:

Login

Subscribe To Drug Industry Daily